3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Leukemia, Myelomonocytic, Chronic
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Hepatoblastoma
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
GATA2 Deficiency
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Anemia, Refractory
1
Interventions
Dexamethasone
114
daratumumab
68
Lenalidomide
66
Bortezomib
55
pomalidomide
44
carfilzomib
39
Cyclophosphamide
33
Specimen Handling
30
Calcium Dobesilate
30
Biopsy
27
Magnetic Resonance Spectroscopy
24
belantamab mafodotin
20
isatuximab
19
fludarabine
17
talquetamab
16
iberdomide
15
Melphalan
15
dexamethasone acetate
13
dexamethasone 21-phosphate
13
auricularum
13
fludarabine phosphate
11
selinexor
10
elotuzumab
10
tocilizumab
9
X-Rays
8
Nivolumab
8
Sirolimus
7
trametinib
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Vorinostat
×
90 days
×
Clear all
NCT01502085
2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2
Completed
25 enrolled
5 charts
NCT01297764
2026-03-23
QUAD
Hackensack Meridian Health
Phase 1/2
Active not recruiting
17 enrolled